. 2023 Sep 12;51(1):245–257. doi: 10.1007/s00259-023-06416-9

Table 4.

Reproducibility coefficient (RDC) values and grade from TARGET round robin substudy compared with published data

Study/publication	Number of patients; number of reviewers	Imaging modality	RDC (95% CI) for NTAD	RDC (95% CI) for TAD
Haste et al., .2017 [22]	73 and 63 patients^a 3 reviewers	^99mTc-MAA SPECT ^b	WLNT (grade 2)^d 1.4 (1.4 to 1.5)	Tumour (grade 4)^d 2.4 (2.2 to 3.2)
⁹⁰Y PET	WLNT (grade 2)^d 1.4 (1.3 to 1.6)	Tumour (grade 2)^d 1.6 (1.5 to 1.8)
Meyers et al., 2020 [19]	23 patients 3 reviewers	⁹⁰Y PET	WLNT (grade 2)^d 1.33 (1.26 to 1.68)	Tumour (grade 3)^d 1.52 (1.38 to 2.25)
TARGET round robin	20 patients 8 reviewers	^99mTc-MAA SPECT segmentation ^c	WLNT (grade 4)^d 3.62 (2.98 to 6.95) Perfused normal tissue (grade 3)^d 1.75 (1.62 to 2.31)	Total perfused tumours (grade 4)^d 2.78 (2.29 to 5.24) Target lesion (grade 4)^d 2.84 (2.33 to 5.41)
Anatomic segmentation ^c	WLNT (grade 3)^d 1.85 (1.69 to 2.52) Perfused normal tissue (grade 3)^d 1.46 (1.39 to 2.25)	Total perfused tumours (grade 3)^d 1.84 (1.66 to 2.56) Target lesion (grade 4)^d 2.07 (1.87 to 3.10)

Study/publication

Number of patients; number of reviewers

Imaging modality

RDC (95% CI) for NTAD

RDC (95% CI) for TAD

Haste et al., .2017 [22]

73 and 63 patients^a

3 reviewers

^99mTc-MAA

SPECT ^b

WLNT (grade 2)^d

1.4 (1.4 to 1.5)

Tumour (grade 4)^d

2.4 (2.2 to 3.2)

⁹⁰Y PET

WLNT (grade 2)^d

1.4 (1.3 to 1.6)

Tumour (grade 2)^d

1.6 (1.5 to 1.8)

Meyers et al., 2020 [19]

23 patients

3 reviewers

⁹⁰Y PET

WLNT (grade 2)^d

1.33 (1.26 to 1.68)

Tumour (grade 3)^d

1.52 (1.38 to 2.25)

TARGET round robin

20 patients

8 reviewers

^99mTc-MAA SPECT segmentation ^c

WLNT (grade 4)^d

3.62 (2.98 to 6.95)

Perfused normal tissue (grade 3)^d

1.75 (1.62 to 2.31)

Total perfused tumours (grade 4)^d

2.78 (2.29 to 5.24)

Target lesion (grade 4)^d

2.84 (2.33 to 5.41)

Anatomic segmentation ^c

WLNT (grade 3)^d

1.85 (1.69 to 2.52)

Perfused normal tissue (grade 3)^d

1.46 (1.39 to 2.25)

Total perfused tumours (grade 3)^d

1.84 (1.66 to 2.56)

Target lesion (grade 4)^d

2.07 (1.87 to 3.10)

WLNT, whole liver normal tissue

^aWLNT absorbed dose was assessed in 73 patients; TAD was assessed in 63 patients, with only the largest tumour being assessed for patients with multiple tumours

^bHaste et al. used ^99mTc-MAA SPECT rather than ^99mTc-MAA SPECT/CT

^cTARGET round robin used ^99mTc-MAA SPECT/CT and diagnostic CT or MRI imaging

^dGrade assigned based on Table 2